Collectively, our findings support the notion that catalpol exerts its therapeutic effects on diabetic nephropathy possibly by down-regulating Grb10 expression and the subsequent activation of IGF-1/IGF-1R signaling. Here, GRB10 is linked to diabetic kidney disease.